Quick Listen: Scrip’s Five Must-Know Things
In this week's podcast episode of Five Must-Know Things, hear about GSK coming under pressure from investors; BMS focusing on a promising oncology target in a new deal; Sanofi’s COVID-19 vaccine challenges; China's progress with mRNA coronavirus vaccines; and new headwinds for Pfizer’s Ibrance.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 21 May 2021, including: GSK comes under pressure from investors; BMS focuses on a promising oncology target in a new deal; Sanofi’s COVID-19 vaccine faces challenges; China progresses its mRNA expertise for new coronavirus vaccines; and Pfizer’s Ibrance faces new headwinds.
These and all other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud and TuneIn - and also now on Spotify Podcasts - and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Walmsley Under Pressure Over GSK’s Strategy" - Scrip, 19 May, 2021.)
(Also see "Bristol Pays Out $200m For Agenus' Preclinical Bispecific TIGIT" - Scrip, 18 May, 2021.)
(Also see "Sanofi Sees Booster Role For Covid Vaccine After Solid But Underwhelming Results" - Scrip, 17 May, 2021.)
(Also see "How A Small Chinese Biotech Is Taking On mRNA Vaccine Giants" - Scrip, 14 May, 2021.)
(Also see "CDK4/6 Market: Is A Shakeup Underway?" - Scrip, 13 May, 2021.)